Syntekabio Inc. Selected for Ministry of SMEs 2024 Industry-Academia-Research Collabo 研发 Program... Commencing AI-Based Psoriasis Treatment Development
▶ Syntekabio-西江大学, RudaCure-仁济大学... Synergy expected through multidisciplinary collaboration
▶ Government 研发 support to foster national strategic technologies and regional strategic industries
Syntekabio Inc. (CEO Jongsun Jeong) announced that it has been selected for the '2024 Industry-Academia-Research Collabo 研发' program (preliminary research) supported by the 中小企业部 and signed the agreement on the 12th.
This research aims to discover 创新药物候选物s for 银屑病 treatment and will demonstrate the efficiency of an AI-based 药物开发 platform.
Syntekabio has formed an industry-academia-research consortium with RudaCure Inc., 西江大学, and 仁济大学 to jointly conduct this research. The research topic is 'Development of selective modulators for 银屑病 target proteins using an AI drug platform,' with a total research period from May 2025 to May 2026.
Syntekabio's AI 药物开发 platform 'STB' was used for computer-based target protein analysis and candidate compound discovery. RudaCure's TRPV1 modulation technology expertise provides specialized knowledge in skin disease-related 离子通道 research. 西江大学 is responsible for compound synthesis and optimization, while 仁济大学 handles in-vitro and in-vivo 疗效 evaluation of candidate compounds.
CEO Jongsun Jeong of Syntekabio stated, "Through AI-based 药物开发, we will pioneer new possibilities in the 银屑病 treatment market. Through collaboration with excellent partners like RudaCure, 西江大学, and 仁济大学, we expect outstanding results."